Gene editing stocks get mentioned in the same breath as the “Imperium” pitch, but they are a neighboring technology rather than part of it. Where the pitch is about writing new DNA from scratch, gene editing is about rewriting the DNA that is already inside a living cell. This article explains the difference, names the CRISPR companies that anchor the category, and shows how the two fields connect.

Editing vs. Writing

The distinction is the difference between a find-and-replace and a fresh document. DNA synthesis, the write step at the center of the Imperium pitch, builds a brand-new sequence from nothing. Gene editing, by contrast, reaches into an existing genome and changes specific letters or stretches of code in place.

Both are forms of genetic engineering, but they are used for different jobs. If you want a cell to make a protein it has never made, you write new DNA and insert it. If you want to fix a broken gene inside a cell that is already alive and dividing, you edit. The pitch’s picks, Twist Bioscience and Ginkgo Bioworks, sit in the write layer, not the edit layer, which is a distinction worth keeping straight before you buy anything.

What CRISPR Actually Does

CRISPR is the tool that made editing practical. It works like a guided search-and-replace: a short piece of RNA leads a cutting enzyme to a precise spot in the genome, the enzyme makes a cut, and the cell’s own repair machinery is then used to delete, correct, or insert genetic material at that spot.

Before CRISPR, editing a specific gene was slow, expensive, and imprecise. CRISPR made it programmable, which is why it won its inventors a Nobel Prize and why an entire category of companies now trades on the technology. It is a genuinely powerful tool, and it is the reason editing is often discussed alongside the read-and-write stack even though it is a distinct step. For the broader map of how all these layers fit together, our synthetic biology piece is the right starting point.

The Edit-Layer Names

The editing category is anchored by a handful of pure-play CRISPR companies, each working the same core science with a different emphasis. CRISPR Therapeutics focuses on blood disorders and has pushed a sickle-cell therapy to approval. Intellia Therapeutics works on in vivo editing, editing genes inside the body rather than in a dish, with liver and rare-disease programs. Editas Medicine targets ocular and other diseases, and Beam Therapeutics works on base editing, a more precise variant that changes single letters without cutting the strand.

These are early-stage biotech companies, and their value swings on clinical results rather than revenue growth, which makes them a different risk profile from the synthesis names. The briefs for this batch ask us not to invent prices or forward estimates for these names, so the honest way to describe them is by program and stage, which is what matters anyway. If you want the read and write layer leaders with their actual financials, our genomics stocks survey names them with tickers.

How Editing Relates to the Imperium Thesis

The pitch itself does not put editing at its center. Its three layers are Twist Bioscience as silicon, Ginkgo Bioworks as software, and Absci as the apps layer, all of which are read-write-program businesses rather than editing businesses. Editing is the adjacent technology that shares the same underlying science and the same investor audience.

There is still a real relationship. The same cheap DNA synthesis that makes the write layer work also produces the guide RNA and reagents that editing depends on, so the two fields buy from the same suppliers. A world where writing DNA is cheap is also a world where editing becomes cheaper, because both ride the same cost curve. That is the honest connection: the Imperium thesis and the editing names are neighbors that share an input, not the same bet.

The Honest Frame

For an investor weighing the category, the useful distinction is maturity and risk. The editing names are earlier and more binary than the synthesis names, because their value depends on clinical readouts, and the synthesis names at least have growing revenue to point to. Neither is a diversified holding, and both carry biotech-level volatility.

The practical rule is to know which layer you are actually buying. If the appeal is the write layer, that is Twist and its neighbors, covered in depth in our Twist Bioscience stock piece. If the appeal is the edit layer, that is the CRISPR names above, and they are a separate, earlier bet that deserves its own due diligence rather than a piggyback on the pitch.

A Category That Rewards Patience

Gene editing is a long-horizon category, and the names in it are priced on clinical milestones rather than revenue. That means the right posture is patience and position sizing rather than conviction in a single readout. The science is real and improving, but the gap between a promising edit and an approved therapy is measured in years, and not every program crosses it. For most investors, the edit layer is best understood as a watchlist rather than a core position.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.